Abstract 322P
Background
There is limited evidence regarding the prognostic value of the three-tier chemotherapy response score (CRS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the impact of CRS on survival in advanced EOC.
Methods
This prospective single-centre study included consecutive women with stage IIIC-IV EOC who underwent interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) at Tata Medical Center between March 2021 and June 2022. Clinical characteristics, progression-free survival (PFS), and overall survival (OS) were compared between the CRS groups.
Results
Among the 102 women treated with NACT followed by IDS, CRS 1 was found in 16 (15.7%), CRS 2 in 66 (64.7%), and CRS 3 in 20 (19.6%). Age, stage, and BRCA status were not different across CRS groups. The patients with CRS 3 had significantly longer PFS than the other CRS groups (median PFS 17 months, 19.8 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.001). Estimated OS was also significantly longer in those with CRS 3 (median OS 22.2 months, 33 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.035). The PFS and OS differences remained statistically significant in univariate and multivariate analyses.
Conclusions
Chemotherapy response score 3 was associated with improved survival in advanced EOC treated with NACT. The prognostic value of CRS can be used in future studies of response-adapted adjuvant or maintenance treatment in advanced EOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract